[{"id":"569368a9-e762-49bc-b3b0-d10e7bc1381f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02390752","created_at":"2021-01-18T11:23:54.887Z","updated_at":"2025-02-25T16:58:46.439Z","phase":"Phase 1","brief_title":"Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...","source_id_and_acronym":"NCT02390752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 04/29/2015","start_date":" 04/29/2015","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"02589ea2-b55d-4c53-8a30-8e1c0d408718","acronym":"","url":"https://clinicaltrials.gov/study/NCT04955535","created_at":"2021-07-08T14:52:54.041Z","updated_at":"2024-07-02T16:36:28.186Z","phase":"","brief_title":"Screening of Specific Genes for Pigmented Villous Nodular Synovitis","source_id_and_acronym":"NCT04955535","lead_sponsor":"Peking University Third Hospital","biomarkers":" TNFA • CSF1 • IL1B","pipe":"","alterations":" ","tags":["TNFA • CSF1 • IL1B"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 08/03/2020","start_date":" 08/03/2020","primary_txt":" Primary completion: 12/27/2020","primary_completion_date":" 12/27/2020","study_txt":" Completion: 12/27/2020","study_completion_date":" 12/27/2020","last_update_posted":"2021-07-08"},{"id":"b4bb2d6f-d75f-4210-91cf-04cc081ab22c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291288","created_at":"2024-02-16T08:18:36.953Z","updated_at":"2024-07-02T16:36:30.252Z","phase":"Phase 1","brief_title":"Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)","source_id_and_acronym":"NCT03291288","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 02/26/2018","start_date":" 02/26/2018","primary_txt":" Primary completion: 09/26/2018","primary_completion_date":" 09/26/2018","study_txt":" Completion: 04/16/2021","study_completion_date":" 04/16/2021","last_update_posted":"2021-05-14"},{"id":"ae04c4b0-5e58-41e5-a5a2-7672c264f891","acronym":"","url":"https://clinicaltrials.gov/study/NCT01643850","created_at":"2021-01-18T07:04:45.792Z","updated_at":"2024-07-02T16:36:36.582Z","phase":"Phase 2","brief_title":"MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)","source_id_and_acronym":"NCT01643850","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CSF1 • CD14","pipe":"","alterations":" ","tags":["CSF1 • CD14"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lacnotuzumab (MCS110)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 04/23/2012","start_date":" 04/23/2012","primary_txt":" Primary completion: 12/07/2017","primary_completion_date":" 12/07/2017","study_txt":" Completion: 12/21/2018","study_completion_date":" 12/21/2018","last_update_posted":"2021-01-05"}]